Natera is trading 15.91% down at $265.69 after-hours on August 12, 2026, with no reliable company-specific explanation identified for the decline.

  • Natera closed the regular session at $315.96.
  • Natera announced a collaboration supporting a Phase 1 skin-cancer trial using its Latitude assay; the release cited no negative financial or operational development and did not attribute stock movement to the announcement.
  • The broader market was modestly positive, making macro pressure an unlikely explanation.